• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.79 -0.29 (-1.03%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 912,395
Open 28.50
Bid (Size) 27.00 (1,500)
Ask (Size) 33.00 (200)
Prev. Close 28.08
Today's Range 27.64 - 28.81
52wk Range 10.83 - 41.14
Shares Outstanding 67,176,067
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment ↗
Today 3:02 EDT
Amylyx Pharmaceuticals (NASDAQ:AMLX) said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to... 
Via MarketBeat
News headline image
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
September 23, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire

Performance

52-Week Range 32.5% below 52-week high
27.79
10.8352W Low 41.1452W High
1 Week 7.8% below 1-week high
27.551W Low 30.141W High

Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX) traded between $10.83 and $41.14 over the past 52 weeks and last traded at $27.79, 32.5% below its 52-week high. Over the past week it ranged between $27.55 and $30.14.

Past 12 Months
-6.9%
-19.4%
+54.6%
+75.6%
+143.3%
+109.1%
1W -$2.06
1M -$6.70
3M +$9.82
6M +$11.96
YTD +$16.37
1Y +$14.50

AMLX was +109.1% over the past year, +75.6% over six months, +143.3% year to date, -6.9% in the last week.

12 Months vs Market
AMLX
+109.1%
DIA
+9.9%
SPY
+15.0%
QQQ
+23.7%
IWM
+15.4%

Over the past 12 months AMLX returned +109.1% versus DIA (Dow) +9.9%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +23.7% and IWM (Russell 2000) +15.4%.

Volume & Liquidity 0.39× 3-mo avg
Today 912,395 3-mo avg 2.3M
1W
1.2M
1M
1.4M
3M
2.3M
6M
1.9M
YTD
1.7M
1Y
1.6M

AMLX most recently traded 912,395 shares against a 3-month average daily volume of 2.3M.

More News

Read More
News headline image
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
September 08, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? ↗
September 01, 2026
Via The Motley Fool
Amylyx Pharmaceuticals (NASDAQ:AMLX) Misses on Q2 Bottom Line as LUCIDITY Readout Looms ↗
August 06, 2026
Via Chartmill
News headline image
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? ↗
August 30, 2026
Via The Motley Fool
News headline image
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week ↗
August 21, 2026
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
August 19, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Amylyx Pharmaceuticals Stock Skyrocketed Today ↗
August 18, 2026
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
August 18, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
August 18, 2026
Via Benzinga
News headline image
Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55% ↗
August 18, 2026
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
August 18, 2026
Via Benzinga
News headline image
Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
August 18, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Announce Topline Results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia on August 18, 2026
August 17, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx (AMLX) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Amylyx Pharmaceuticals Q2 Earnings Call Highlights ↗
August 06, 2026
Via MarketBeat
Topics Earnings
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results
August 06, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
August 03, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
June 23, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape ↗
June 10, 2026
Via MarketBeat
News headline image
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
June 08, 2026
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
What to Know About This Fund's $10 Million Bet on Gold Miners ↗
May 24, 2026
Via The Motley Fool
Topics Economy
News headline image
Amylyx Stock: Why the Full Pipeline Story Matters ↗
May 24, 2026
Via MarketBeat
News headline image
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares ↗
May 19, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Amylyx Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Amylyx Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Amylyx Pharmaceuticals, Inc. - Common Stock trade on?
Amylyx Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Amylyx Pharmaceuticals, Inc. - Common Stock is AMLX on the Nasdaq Stock Market
What is the current price of Amylyx Pharmaceuticals, Inc. - Common Stock?
The current price of Amylyx Pharmaceuticals, Inc. - Common Stock is 27.79
When was Amylyx Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Amylyx Pharmaceuticals, Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Amylyx Pharmaceuticals, Inc. - Common Stock is 1.87B
How many shares of Amylyx Pharmaceuticals, Inc. - Common Stock are outstanding?
Amylyx Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap